EU PHARMA COMPANIES SET TO BENEFIT FROM CANADIAN TRADE DEAL
November 3rd, 2013
EUROPEAN Union (EU) pharma companies are set to benefit from a new free trade deal struck between the EU and Canada, with Canada liberalising its patent protection rules. Once the Comprehensive Economic and Trade Agreement (CETA) has been ratified (probably in 2015), Canada will lock its practice of providing eight years’ market exclusivity, with a six year block on applications for generic drugs, and a two-year ‘no-marketing’ period when generic manufacturers can prepare medicines for sale.Also, Canada will offer weaker additional (sui generis) protection ...
Full access to this article can be arranged with permission from the client that first ordered it. Please contact us to request access. Entries are uploaded to our archive at least one year after being published by a client – free access is restricted to International News Services journalists for background research only. The article date indicates when copy was filed to a client, not when posted to this archive. Upon client requests, International News Services will remove such articles from the archive or not upload them in the first place. They are included to demonstrate the breadth of topics undertaken by the agency and also to help promote clients’ coverage.